Identification of novel,<i>in vivo</i>active Chk1 inhibitors utilizing structure guided drug design
Andrew J. Massey(Clatterbridge Cancer Centre NHS Foundation Trust), Mike Wood(University of Oxford)
Cited by 44
Related Papers
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
|BMC Cancer|2014|110
Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
|Molecular Cancer|2014|53
Multiparametric Cell Cycle Analysis Using the Operetta High-Content Imager and Harmony Software with PhenoLOGIC
|PLoS ONE|2015|46
γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
|BMC Cancer|2014|33
mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
|Molecular Oncology|2015|24